Clinical Trial Update: Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI [Phase 1, Phase 2]

View source ↗

Summary

This Clinical Trial Update describes a Phase 1/2 study of Vebreltinib plus PLB1004 in EGFR-mutated, advanced non-small cell lung cancer with MET amplification o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PLB1004
• Vebreltinib (vebreltinib)

Snippet

Sponsor: Avistone Biotechnology Co., Ltd. | Conditions: Non-Small-Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING